LeMaitre Vascular, Inc.
NASDAQ•LMAT
CEO: Mr. George W. LeMaitre
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2006-10-19
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Contact Information
Market Cap
$2.44B
P/E (TTM)
42.2
58.6
Dividend Yield
0.7%
52W High
$115.33
52W Low
$71.42
52W Range
Rank23Top 9.4%
5.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$64.45M+0.00%
4-Quarter Trend
EPS
$0.69+0.00%
4-Quarter Trend
FCF
$0.00+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Sales Growth 14% Net sales reached $249.6M USD, marking a 14% increase driven by higher average selling prices and unit volumes.
Gross Margin Expansion Gross profit grew 18% to $178.5M USD; margin improved 290 basis points to 71.5% aided by ERC receipt.
Strong Operating Cash Flow Cash provided by operations was $81.3M USD, a significant increase from $44.1M USD reported in the prior year.
Dividend Rate Increased Board approved $0.25 per share dividend in Feb 2026, up from $0.20 per share paid quarterly throughout 2025.
Risk Factors
Profit Growth Sustainability Historical operating income growth drivers like pricing increases may slow or disappear if favorable factors are not replicated.
Supply Chain Reliance Risk Dependence on sole or limited-source suppliers for critical components, including biologic and tissue-based products, exposes production.
Cybersecurity Incident Exposure Experienced a cybersecurity incident in January 2026; ongoing investigation may result in future liability or operational disruption.
Regulatory Approval Hurdles Failure to obtain and maintain regulatory clearances in various geographies could limit ability to sell products and hamper growth.
Outlook
Direct Sales Force Expansion Intend to further expand direct sales force, which comprised 160 representatives at year-end 2025, to penetrate new markets.
Acquisition Growth Strategy Will continue using acquisitions as primary means to penetrate peripheral vascular device market segments and add complementary products.
Manufacturing Consolidation Timeline Transferring majority of allograft tissue processing operations from Fox River Grove to Burlington facility, expected completion by end of 2026.
Share Repurchase Authorization Board authorized $100.0M USD share repurchase program through February 2027 to return capital to common stockholders.
Peer Comparison
Revenue (TTM)
$6.33B
$3.31B
$2.73B
Gross Margin (Latest Quarter)
90.7%
86.6%
74.4%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| HAE | $2.99B | 17.0 | 20.3% | 49.2% |
| TWST | $2.81B | -36.6 | -16.6% | 28.8% |
| NHC | $2.66B | 22.1 | 11.6% | 5.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.5%
Moderate Growth
4Q Net Income CAGR
12.3%
Profitability Improving
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:Apr 29, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data